F Fitzal
Overview
Explore the profile of F Fitzal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
689
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singer C, Jahn S, Rudas M, Bago-Horvath Z, Fitzal F, Abete L, et al.
Breast
. 2022 Jun;
64:127-133.
PMID: 35689881
Purpose: To validate the prognostic role of urokinase-type plasminogen-activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) protein expression in FFPE archived tumor samples when assessed by immunohistochemistry. Patients And Methods:...
2.
Minichsdorfer C, Fuereder T, Leutner M, Singer C, Kacerovsky-Strobl S, Egle D, et al.
ESMO Open
. 2022 Mar;
7(2):100426.
PMID: 35334418
Background: Statins are cholesterol-lowering drugs prescribed for the prevention and treatment of cardiovascular disease. Moreover, statins may possess anticancer properties and interact with receptor activator of nuclear factor κB ligand...
3.
Filipits M, Rudas M, Singer C, Fitzal F, Bago-Horvath Z, Greil R, et al.
ESMO Open
. 2021 Aug;
6(4):100228.
PMID: 34371382
Background: The purpose of this study was to assess the concordance of real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection of ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA)...
4.
Fitzal F, Filipits M, Fesl C, Rudas M, Greil R, Balic M, et al.
Br J Surg
. 2021 Feb;
108(3):308-314.
PMID: 33608712
Background: The aim of this study was to investigate whether the PAM-50-based 46-gene assay carries prognostic value for risk of local recurrence of breast cancer. Methods: The Austrian Breast and...
5.
Bjelic-Radisic V, Fitzal F, Knauer M, Steger G, Egle D, Greil R, et al.
BMC Cancer
. 2020 May;
20(1):392.
PMID: 32375735
Background: The ABCSG-28 trial compared primary surgery followed by systemic therapy versus primary systemic therapy without surgery in patients with de novo stage IV BC. The present report describes QoL...
6.
Wimmer K, Bolliger M, Bago-Horvath Z, Steger G, Kauer-Dorner D, Helfgott R, et al.
Ann Surg Oncol
. 2019 Dec;
27(5):1700-1707.
PMID: 31873929
Background: While "no tumour on ink" is an accepted margin width for R resection in primary surgery, it's unclear if it's oncologically safe after neoadjuvant chemotherapy (NAC). Only limited data...
7.
Singer C, Filipits M, Jahn S, Abete L, Jakesz R, Greil R, et al.
Breast
. 2019 May;
46:101-107.
PMID: 31132475
Background: To evaluate whether uPA/PAI-1 protein in hormone receptor-positive (HR+) breast tumor can predict prognosis in early breast cancer (BC). Methods: 606 women with HR + BC who had ≥5...
8.
Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, et al.
Br J Cancer
. 2015 Apr;
112(8):1405-10.
PMID: 25867274
Background: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast...
9.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al.
Ann Oncol
. 2014 Nov;
26(2):313-20.
PMID: 25403582
Background: Zoledronic acid (ZOL) plus adjuvant endocrine therapy significantly improved disease-free survival (DFS) at 48- and 62-month follow-up in the ABCSG-12 trial. We present efficacy results of a final additional...
10.
Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retel V, Fitzal F, et al.
Br J Cancer
. 2014 Jul;
111(5):837-42.
PMID: 25003667
Background: Validated multigene signatures (MGS) provide additional prognostic information when evaluating clinical features of ER(+), HER2(-) early breast cancer. We have studied the quantitative and qualitative impact of MGS on...